Toward explainable artificial intelligence for precision pathology

F Klauschen, J Dippel, P Keyl… - Annual Review of …, 2024 - annualreviews.org
The rapid development of precision medicine in recent years has started to challenge
diagnostic pathology with respect to its ability to analyze histological images and …

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

JM Llovet, R Pinyol, M Yarchoan, AG Singal… - Nature Reviews …, 2024 - nature.com
Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation

NR Campbell, A Rao, MV Hunter, MK Sznurkowska… - Developmental cell, 2021 - cell.com
Melanomas can have multiple coexisting cell states, including proliferative (PRO) versus
invasive (INV) subpopulations that represent a" go or grow" trade-off; however, how these …

Prognostic biomarkers of cutaneous melanoma

L Ding, A Gosh, DJ Lee, G Emri… - Photodermatology …, 2022 - Wiley Online Library
Background/purpose Melanomas account for only approximately 4% of diagnosed skin
cancers in the United States but are responsible for the majority of deaths caused by skin …

Advancements in melanoma cancer metastasis models

LM Nascentes Melo, S Kumar, V Riess… - Pigment cell & …, 2023 - Wiley Online Library
Metastatic melanoma is a complex and deadly disease. Due to its complexity, the
development of novel therapeutic strategies to inhibit metastatic melanoma remains an …

Identifying the transcriptional drivers of metastasis embedded within localized melanoma

S Suresh, R Rabbie, M Garg, D Lumaquin, TH Huang… - Cancer discovery, 2023 - AACR
In melanoma, predicting which tumors will ultimately metastasize guides treatment
decisions. Transcriptional signatures of primary tumors have been utilized to predict …

Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I–II melanoma patients at risk of disease relapse

EEAP Mulder, I Johansson, DJ Grünhagen, D Tempel… - Cancers, 2022 - mdpi.com
Simple Summary More than 40% of patients initially diagnosed with 'low risk'(stage I–II)
melanoma eventually develop melanoma recurrence or die as a result of melanoma. While …

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome

GH Attrill, H Lee, AT Tasker, NA Adegoke… - Frontiers in …, 2022 - frontiersin.org
While the tumor immune microenvironment (TIME) of metastatic melanoma has been well
characterized, the primary melanoma TIME is comparatively poorly understood. Additionally …

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

X Xu, L Ai, K Hu, L Liang, M Lv, Y Wang, Y Cui… - Nature …, 2024 - nature.com
Immunotherapy confers little to no benefit in the treatment of microsatellite stable (MSS)
metastatic colorectal cancer (mCRC). Mechanistic insights suggested that epidermal growth …

Two subtypes of cutaneous melanoma with distinct mutational signatures and clinico-genomic characteristics

YS Kim, M Lee, YJ Chung - Frontiers in Genetics, 2022 - frontiersin.org
Background: To decipher mutational signatures and their associations with biological
implications in cutaneous melanomas (CMs), including those with a low ultraviolet (UV) …